Cyclerion Therapeutics Inc
CYCN1.690USD
-0.170-9.14%
Fechamento 11/04, 16:00（ET）Cotações atrasadas em 15 min
5.20MValor de mercado
PerdaP/L TTM
Mais detalhes de Cyclerion Therapeutics Inc Empresa
Cyclerion Therapeutics, Inc. is a clinical-stage biopharmaceutical company that focuses on developing treatments for serious diseases. The Company’s portfolio includes novel soluble guanylate cyclase (sGC) stimulators, namely praliciguat and olinciguat, as well as multiple research stage molecules. Praliciguat is a systemic sGC stimulator that is licensed to Akebia Therapeutics, Inc. for the treatment of rare kidney disease. Olinciguat is a vascular sGC stimulator that the Company intends to out-license for cardiovascular diseases. The Company operates through the human therapeutics segment. The Company is focused on identifying non-sGC stimulator assets within the central nervous system (CNS) therapeutic area to build a new portfolio. The Company is also evaluating other activities aimed at enhancing shareholder value, which potentially include collaborations, licenses, mergers, acquisitions and/or other targeted investments.
Informações de Cyclerion Therapeutics Inc
Código da empresaCYCN
Nome da EmpresaCyclerion Therapeutics Inc
Data de listagemMar 18, 2019
CEODr. Regina M. Graul, Ph.D.
Número de funcionários1
Tipo de títulosOrdinary Share
Fim do ano fiscalMar 18
Endereço301 Binney Street
CidadeCAMBRIDGE
Bolsa de valoresNASDAQ Capital Market Consolidated
PaísUnited States of America
Código postal02142
Telefone16176217722
Sitehttps://www.cyclerion.com/
Código da empresaCYCN
Data de listagemMar 18, 2019
CEODr. Regina M. Graul, Ph.D.
Executivos da empresa Cyclerion Therapeutics Inc
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Peter M. Hecht, Ph.D.
Dr. Peter M. Hecht, Ph.D.
Director
Director
559.20K
--
Dr. Errol B. De Souza, Ph.D.
Dr. Errol B. De Souza, Ph.D.
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
50.00K
--
Mr. Michael J. Higgins
Mr. Michael J. Higgins
Independent Director
Independent Director
30.74K
+5.67%
Dr. Dina Katabi, Ph.D.
Dr. Dina Katabi, Ph.D.
Independent Director
Independent Director
20.00K
--
Dr. Regina M. Graul, Ph.D.
Dr. Regina M. Graul, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Ms. Rhonda M. Chicko
Ms. Rhonda M. Chicko
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Steven E. Hyman, M.D.
Dr. Steven E. Hyman, M.D.
Independent Director
Independent Director
--
--
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Peter M. Hecht, Ph.D.
Dr. Peter M. Hecht, Ph.D.
Director
Director
559.20K
--
Dr. Errol B. De Souza, Ph.D.
Dr. Errol B. De Souza, Ph.D.
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
50.00K
--
Mr. Michael J. Higgins
Mr. Michael J. Higgins
Independent Director
Independent Director
30.74K
+5.67%
Dr. Dina Katabi, Ph.D.
Dr. Dina Katabi, Ph.D.
Independent Director
Independent Director
20.00K
--
Dr. Regina M. Graul, Ph.D.
Dr. Regina M. Graul, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Ms. Rhonda M. Chicko
Ms. Rhonda M. Chicko
Chief Financial Officer
Chief Financial Officer
--
--
Detalhamento da receita
Sem dados
Sem dados
Por Empresa
Por Região
Sem dados
Distribuição de ações
Atualizado em: ter, 2 de set
Atualizado em: ter, 2 de set
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
Hecht (Peter M)
16.76%
J. Wood Capital Advisors LLC
5.45%
Tyndall Management, LLC
4.65%
American Endowment Foundation
3.99%
Invus Public Equities Advisors, LLC
3.48%
Outro
65.68%
Investidores
Investidores
Proporção
Hecht (Peter M)
16.76%
J. Wood Capital Advisors LLC
5.45%
Tyndall Management, LLC
4.65%
American Endowment Foundation
3.99%
Invus Public Equities Advisors, LLC
3.48%
Outro
65.68%
Tipos de investidores
Investidores
Proporção
Individual Investor
22.05%
Corporation
9.43%
Investment Advisor
5.69%
Investment Advisor/Hedge Fund
5.63%
Hedge Fund
0.08%
Research Firm
0.03%
Outro
57.09%
Participação acionária institucional
Atualizado em: qua, 1 de out
Atualizado em: qua, 1 de out
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q3
33
381.61K
11.43%
-552.00K
2025Q2
47
1.50M
44.80%
-242.81K
2025Q1
64
1.40M
44.62%
-170.60K
2024Q4
68
1.21M
44.74%
-507.00K
2024Q3
71
1.75M
64.88%
-8.65K
2024Q2
75
1.75M
64.62%
-27.65K
2024Q1
84
1.73M
66.48%
-9.21K
2023Q4
93
1.67M
68.18%
-15.51K
2023Q3
103
1.45M
60.44%
-312.49K
2023Q2
122
1.38M
57.36%
-283.95K
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
Hecht (Peter M)
559.20K
16.76%
--
--
Apr 21, 2025
J. Wood Capital Advisors LLC
181.82K
5.45%
+181.82K
--
Apr 21, 2025
Tyndall Management, LLC
155.19K
4.65%
-9.59K
-5.82%
Jun 30, 2025
American Endowment Foundation
133.03K
3.99%
+133.03K
--
Dec 31, 2024
Invus Public Equities Advisors, LLC
116.16K
3.48%
--
--
Jun 30, 2025
Graul (Regina Margaret)
55.78K
1.67%
-44.52K
-44.39%
Apr 21, 2025
De Souza (Errol B)
50.00K
1.5%
--
--
Apr 21, 2025
Geode Capital Management, L.L.C.
32.73K
0.98%
+1.13K
+3.58%
Jun 30, 2025
Higgins (Michael J)
30.74K
0.92%
+1.65K
+5.67%
Apr 21, 2025
The Vanguard Group, Inc.
23.49K
0.7%
--
--
Jun 30, 2025
Ver Mais
ETFs Relacionados
Atualizado em: dom, 2 de nov
Atualizado em: dom, 2 de nov
Nome
Proporção
Fidelity Nasdaq Composite Index ETF
0%
Fidelity Nasdaq Composite Index ETF
Proporção0%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
May 15, 2023
Merger
20→1
May 15, 2023
Merger
20→1
May 15, 2023
Merger
20→1
May 15, 2023
Merger
20→1
Data
Tipo
Proporção
May 15, 2023
Merger
20→1
May 15, 2023
Merger
20→1
May 15, 2023
Merger
20→1
May 15, 2023
Merger
20→1
